公开(公告)号：WO2021263146A2

公开(公告)日：2021-12-30

申请号：PCT/US2021/039162

申请日：2021-06-25

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： BRYDGES, Susannah ,  KYRATSOUS, Christos ,  BAUM, Alina

IPC: A01K67/027 ,  C07K14/705 ,  C12N9/48 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/0337 ,  A01K67/0275 ,  A01K67/0278 ,  C07K14/70596

Abstract: Non-human animal cells and non-human animals comprising a humanized ACE2 locus and methods of using such non-human animal cells and non-human animals are provided. Non‑human animal cells or non-human animals comprising a humanized ACE2 locus express a human ACE2 protein or a chimeric ACE2 protein, fragments of which are from human ACE2. Methods are also provided for using such non-human animals comprising a humanized ACE2 locus to assess in vivo ACE2 activity, e.g., coronavirus infection and/or the treatment or prevention thereof.

公开(公告)号：WO2023287875A1

公开(公告)日：2023-01-19

申请号：PCT/US2022/036950

申请日：2022-07-13

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： BAUM, Alina ,  KYRATSOUS, Christos ,  YANCOPOULOS, George, D.

IPC: A61P31/14 ,  C07K16/10

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

公开(公告)号：WO2021163076A1

公开(公告)日：2021-08-19

申请号：PCT/US2021/017290

申请日：2021-02-09

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： BAUM, Alina ,  KYRATSOUS, Christos ,  PURCELL, Lisa

IPC: C07K16/40 ,  C07K16/10 ,  A61P31/16 ,  A61P31/14

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections or influenza virus infections).

公开(公告)号：WO2023283134A1

公开(公告)日：2023-01-12

申请号：PCT/US2022/035968

申请日：2022-07-01

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： MURPHY, Andrew ,  KYRATSOUS, Christos ,  BAUM, Alina ,  PETRO, Christopher

IPC: C07K16/10 ,  A61K39/215 ,  A61P31/14

Abstract: Described herein are methods and compositions for directing an antibody response in a subject away from one or more first epitopes of an antigen (e.g., immunodominant epitopes of a vaccine antigen) and towards one or more second epitopes of the antigen by administering one or more antibodies targeting the one or more first epitopes of the antigen.

公开(公告)号：WO2021086899A1

公开(公告)日：2021-05-06

申请号：PCT/US2020/057635

申请日：2020-10-28

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： BAUM, Alina ,  KYRATSOUS, Christos

IPC: C07K16/10 ,  A61K39/42 ,  A61K39/395 ,  A61P31/16

Abstract: Provided herein are monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies are useful for inhibiting or neutralizing influenza B virus activity, thus providing a means of treating or preventing influenza infection in humans. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral attachment and/or entry into host cells. The antibodies may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

公开(公告)号：WO2021242815A1

公开(公告)日：2021-12-02

申请号：PCT/US2021/034187

申请日：2021-05-26

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： BAUM, Alina ,  FULTON, Benjamin ,  KYRATSOUS, Christos ,  YANCOPOULOS, George D.

IPC: C07K16/10 ,  A61P31/14

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

公开(公告)号：WO2021212101A1

公开(公告)日：2021-10-21

申请号：PCT/US2021/027943

申请日：2021-04-19

Applicant: VYRIAD, INC. ,  REGENERON PHARMACEUTICALS, INC.

Inventor： RUSSEL, Stephen J. ,  PENG, Kah Whye ,  LECH, Patrycja ,  BAUM, Alina ,  KYRATSOUS, Christos

IPC: A61K39/12 ,  C07K14/005 ,  C12N7/00

Abstract: The disclosure provides recombinant vesicular stomatitis virus (VSV) particles, wherein the VSV glycoprotein (G) is replaced by a coronavirus spike (S) glycoprotein, or a fragment or a derivative thereof, as well as compositions, vaccines, kits, and methods for using the recombinant VSV particles. In a specific embodiment, the S glycoprotein is derived from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and the methods are for the treatment or prevention of a disease or disorder in a subject infected with SARS-CoV-2. In certain embodiments, the disease or disorder is COVID-19.

公开(公告)号：WO2021151031A1

公开(公告)日：2021-07-29

申请号：PCT/US2021/014802

申请日：2021-01-23

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： BAUM, Alina ,  NITTOLI, Thomas

IPC: A61K47/68 ,  A61K47/6801 ,  A61K47/6839

Abstract: Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with influenza, including VX-787 and derivatives thereof, baloxavir and derivatives thereof, and baloxavir marboxil and derivatives thereof, and protein (e.g., antibody) drug conjugates thereof.

公开(公告)号：WO2021045836A1

公开(公告)日：2021-03-11

申请号：PCT/US2020/039707

申请日：2020-06-25

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： BABB, Robert ,  BAUM, Alina ,  CHEN, Gang ,  GERSON, Cindy ,  HANSEN, Johanna ,  HUANG, Tammy ,  KYRATSOUS, Christos ,  LEE, Wen-Yi ,  MALBEC, Marine ,  MURPHY, Andrew ,  OLSON, William ,  STAHL, Neil ,  YANCOPOULOS, George, D.

IPC: A61K39/215 ,  A61K39/395 ,  A61K45/06 ,  C07K16/10

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections). The present disclosure provides neutralizing human antigen-binding proteins that specifically bind to SARS-CoV-2-S, for example, antibodies or antigen-binding fragments thereof.